Peer Review reports
From: Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study
| Original Submission | ||
|---|---|---|
| 25 Sep 2022 | Submitted | Original manuscript |
| 10 Oct 2022 | Reviewed | Reviewer Report - Nóra Garam |
| 11 Nov 2022 | Reviewed | Reviewer Report |
| 26 Nov 2022 | Reviewed | Reviewer Report - Teresa Cavero |
| 8 Dec 2022 | Author responded | Author comments - Thomas Welte |
| Resubmission - Version 2 | ||
| 8 Dec 2022 | Submitted | Manuscript version 2 |
| 9 Dec 2022 | Author responded | Author comments - Thomas Welte |
| Resubmission - Version 3 | ||
| 9 Dec 2022 | Submitted | Manuscript version 3 |
| 22 Dec 2022 | Reviewed | Reviewer Report - Teresa Cavero |
| 27 Dec 2022 | Reviewed | Reviewer Report - Nóra Garam |
| 28 Dec 2022 | Author responded | Author comments - Thomas Welte |
| Resubmission - Version 4 | ||
| 28 Dec 2022 | Submitted | Manuscript version 4 |
| 2 Jan 2023 | Reviewed | Reviewer Report - Nóra Garam |
| Resubmission - Version 5 | ||
| Submitted | Manuscript version 5 | |
| Publishing | ||
| 3 Jan 2023 | Editorially accepted | |
| 11 Jan 2023 | Article published | 10.1186/s12882-023-03058-9 |
You can find further information about peer review here.